BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mittlmeier LM, Todica A, Gildehaus FJ, Unterrainer M, Beyer L, Brendel M, Albert NL, Ledderose ST, Vettermann FJ, Schott M, Rodler S, Marcon J, Ilhan H, Cyran CC, Stief CG, Staehler M, Bartenstein P. 68Ga-EMP-100 PET/CT-a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma-first in-human biodistribution and imaging results. Eur J Nucl Med Mol Imaging 2021. [PMID: 34708249 DOI: 10.1007/s00259-021-05596-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Machiraju D, Hassel JC. Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1068029] [Reference Citation Analysis]
2 Unterrainer LM, Todica A, Beyer L, Brendel M, Holzgreve A, Kauffmann-Guerrero D, Unterrainer M, Bartenstein P, Tufman A. (68)Ga-EMP-100 PET/CT-a novel method for non-invasive assessment of c-MET expression in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2023;50:628-9. [PMID: 36253641 DOI: 10.1007/s00259-022-05995-3] [Reference Citation Analysis]
3 Flörsch B, Taugner J, Käsmann L, Kenndoff S, Guggenberger J, Tufman A, Reinmuth N, Duell T, Belka C, Eze C, Manapov F. Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis. J Cancer Res Clin Oncol 2022. [PMID: 35915184 DOI: 10.1007/s00432-022-04174-z] [Reference Citation Analysis]
4 Floresta G, Abbate V. Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography. Med Res Rev 2022. [PMID: 35292998 DOI: 10.1002/med.21885] [Reference Citation Analysis]
5 Urso L, Castello A, Rocca GC, Lancia F, Panareo S, Cittanti C, Uccelli L, Florimonte L, Castellani M, Ippolito C, Frassoldati A, Bartolomei M. Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol 2022. [PMID: 35217902 DOI: 10.1007/s00432-022-03958-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]